



2-Day Split-Dosing

If you're starting PLENVU[®] the **evening** before your colonoscopy,
Here's How to Prep

Date of colonoscopy: ____/____/____

Location of colonoscopy: _____

Time of colonoscopy: _____ AM/PM

Nothing to drink after: _____ AM/PM

EVENING

PLENVU[®] Dose 1:

Date: ____/____/____

Day of Week: M T W Th F S Su

Time: _____ PM

MORNING

PLENVU[®] Dose 2:

Date: ____/____/____

Day of Week: M T W Th F S Su

Time: _____ AM

EVENING

DOSE 1

16 oz 16 oz

MANGO FLAVOR

MORNING

DOSE 2

16 oz 16 oz

FRUIT PUNCH FLAVOR

WAIT APPROXIMATELY **12 HOURS** FROM THE START OF DOSE 1

READY FOR COLONOSCOPY

Note: actual solution is clear.

Stop drinking liquids at least 2 hours before your colonoscopy or as recommended by your healthcare provider.



TAKE DOSE 1

1. Use the mixing container to mix the contents of the Dose 1 pouch with at least 16 ounces of water by shaking or using a spoon until it's completely dissolved. This may take up to 2 to 3 minutes. Take your time—slowly finish the dose within 30 minutes.
2. Refill the container with at least 16 ounces of clear liquid. Again, take your time and slowly finish all of it within 30 minutes.

WAIT APPROXIMATELY 12 HOURS FROM THE START OF DOSE 1, THEN...

TAKE DOSE 2

1. Use the mixing container to mix the contents of Dose 2 (Pouch A and Pouch B) with at least 16 ounces of water by shaking or using a spoon until it's completely dissolved. This may take up to 2 to 3 minutes. Take your time—slowly finish the dose within 30 minutes.
2. Refill the container with at least 16 ounces of clear liquid. Again, take your time and slowly finish all of it within 30 minutes.

HELPFUL TIP: PLENVU[®] can be refrigerated. Use within 6 hours after it's mixed with water

INDICATION

PLENVU[®] (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride for oral solution) is a prescription medication used by adults to clean the colon before a colonoscopy.

IMPORTANT SAFETY INFORMATION

- Do not take PLENVU[®] if you have a blockage in your intestine (bowel obstruction), an opening in the wall of your stomach or intestine

(bowel perforation), problems with food or fluid emptying from your stomach (gastric retention), a problem with food moving too slowly through your intestines (ileus), a very dilated large intestine, or an allergy to any of the ingredients in PLENVU[®].

Please see additional Important Safety Information on back and accompanying full Prescribing Information, including Medication Guide and Instructions for Use.

Stay Hydrated for Prep Success

It's important to stay hydrated before, during, and after taking PLENVU[®].

You don't need to drink only water—you can have your choice of clear liquids. Examples of clear liquids include

- Clear soda
- Clear broth soups
- Strained lemonade or limeade
- Gelatin (without fruit or toppings)
- Sports drinks
- Watered-down clear fruit juice (with no pulp)
- Coffee/tea (without milk)
- Popsicles (without pieces of fruit or pulp)

Do not drink alcohol, milk, red or purple colored liquids, or anything containing pulp.

Stop drinking liquids **at least 2 hours before your colonoscopy** or as recommended by your healthcare provider.

For more information about PLENVU[®], visit myPLENVU.com or call the toll-free 24-hour hotline at **1-855-MY-PLENVU**

IMPORTANT SAFETY INFORMATION *(continued)*

- It is important to drink sufficient clear liquids before, during, and after the use of PLENVU[®]. Be sure to consume additional clear liquids after the first dose and second dose of PLENVU[®]. Stop drinking liquids 2 hours prior to colonoscopy.
- Before you take PLENVU[®], talk to your doctor if you:
 - Have problems with serious loss of body fluid (dehydration) and changes in blood salts (electrolytes).
 - Have heart problems or take medication that affects your heart. Your doctor may consider obtaining an electrocardiogram (ECG) test if you are at an increased risk for heart rhythm abnormalities.
 - Have a history of seizures or take antiseizure medication.
 - Have kidney problems or take medication that affects kidney function. Your doctor may want to perform blood testing before and after your colonoscopy.
 - Have a history of stomach or bowel problems, such as ulcerative colitis, a bowel blockage, or a suspected opening in the wall of your stomach or intestine.
 - Have problems swallowing, heartburn (gastric reflux), or if you inhale food or fluid into your lungs when eating or drinking (aspirate).
 - Have a condition that destroys red blood cells, called glucose-6-phosphate dehydrogenase (G6PD) deficiency.
 - Are withdrawing from drinking alcohol.
 - Have phenylketonuria (PKU). PLENVU[®] contains aspartame equivalent to 491 mg of phenylalanine per treatment.
- Are pregnant or plan to become pregnant.
- Are breastfeeding or plan to breastfeed.
- PLENVU[®] may affect how other medications work. Tell your doctor about all other medications (including prescription and nonprescription medicines, vitamins, and herbal supplements) you take before you take PLENVU[®]. Do not take oral medications within 1 hour before or after starting each dose of PLENVU[®].
- Symptoms of serious allergic reactions may include skin rash, itching, raised red patches on your skin (hives), swelling of the face, lips, tongue, and throat, and kidney problems.
- In clinical studies with PLENVU[®], the most common side effects in patients taking PLENVU[®] were nausea, vomiting, dehydration, and abdominal pain/discomfort.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center

Phone: 1-800-321-4576

Fax: 1-510-595-8183

Email: salixmc@dlss.com

Please see additional Important Safety Information on front and accompanying full Prescribing Information, including Medication Guide and Instructions for Use.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PLENUV safely and effectively. See full prescribing information for PLENUV.

PLENUV® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution)
Initial U.S. Approval: 2006

INDICATIONS AND USAGE

PLENUV is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. (1)

DOSAGE AND ADMINISTRATION

Preparation and Administration:

- Two doses of PLENUV are required for a complete preparation for colonoscopy, using a “Two-Day” or “One-Day” dosing regimen. (2.1)
- PLENUV must be reconstituted in water prior to ingestion. (2.1)
- Additional clear liquids must be consumed after each dose of PLENUV in both dosing regimens. (2.1, 5.1)
- Do not take oral medications within 1 hour of starting each dose. (2.1, 7.2)

Dosing Regimen:

- Two-Day:** Dose 1 the evening before the colonoscopy (approximately 4 pm to 8 pm) and Dose 2 the next morning (approximately 12 hours after the start of Dose 1). (2.1, 2.2)
 - One-Day:** Dose 1 the morning of the colonoscopy (approximately 3 am to 7 am) and Dose 2 a minimum of 2 hours after the start of Dose 1. (2.1, 2.3)
- For complete information on dosing, preparation and administration see full prescribing information. (2.1, 2.2, 2.3)

DOSAGE FORMS AND STRENGTHS

- For Oral Solution: First dose: one pouch labeled Dose 1; Second dose: two pouches labeled Dose 2 Pouch A and Dose 2 Pouch B.
- Dose 1 contains 100 grams of polyethylene glycol (PEG) 3350, NF; 9 grams of sodium sulfate, NF; 2 grams of sodium chloride, USP/NF; and 1 gram of potassium chloride, USP/NF. (3)
 - Dose 2 Pouch A contains 40 grams of PEG 3350, NF; 3.2 grams of sodium chloride, USP/NF; and 1.2 grams of potassium chloride, USP/NF. (3)
 - Dose 2 Pouch B contains 48.11 grams of sodium ascorbate, USP/NF; and 7.54 grams of ascorbic acid, USP/NF. (3)

Overall Grade	Description
A	All five segments ¹ scored 3 or 4 (Mucosa is fully visualized without cleaning.)
B	One or more segments scored 2, remaining segments scored 3 or 4 (Mucosa is fully visualized.)
C	One or more segments scored 1, remaining segments scored 2, 3 or 4
D	One or more segments scored 0

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- Important Preparation and Administration Instructions
- Two-Day Split-Dosing Regimen
- One-Day Morning Dosing Regimen

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- Serious Fluid and Electrolyte Abnormalities
 - Cardiac Arrhythmias
 - Seizures
 - Use in Patients with Renal Impairment
 - Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis
 - Use in Patients with Significant Gastrointestinal Disease
 - Aspiration
 - Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency
 - Risks in Patients with Phenyleketonuria
 - Hypersensitivity Reactions
- 6 ADVERSE REACTIONS**
- Clinical Trials Experience
 - Postmarketing Experience

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

PLENUV[®] is indicated for cleansing of the colon in preparation for colonoscopy in adults.

2 DOSAGE AND ADMINISTRATION

2.1 Important Preparation and Administration Instructions

- Correct fluid and electrolyte abnormalities before treatment with PLENUV [see *Warnings and Precautions* (5.1)].

Two doses of PLENUV are required for a complete preparation for colonoscopy. The time interval between the two doses depends on the regimen prescribed and the planned timing of the colonoscopy procedure [see *Dosage and Administration* (2.2, 2.3)].

- The “Two-Day Split-Dosing” method consists of two separate doses: the first dose is taken the evening before the colonoscopy and the second dose is taken the next day, the morning of the day of the colonoscopy [see *Dosage and Administration* (2.2)].
- The “One-Day Morning Dosing” method consists of two separate doses: both doses are taken in the morning of the day of the colonoscopy, with a minimum of 2 hours between the start of the first dose and the start of the second dose [see *Dosage and Administration* (2.3)].

- PLENUV must be reconstituted in water prior to ingestion. It may take 2 to 3 minutes for complete dissolution.
- Additional clear liquids (including water) must be consumed in both dosing regimens [see *Dosage and Administration* (2.2, 2.3), *Warnings and Precautions* (5.1)].
- Consume only clear liquids (no solid food) from the start of PLENUV treatment until after the colonoscopy.

- Do not eat or drink alcohol, milk, anything colored red or purple or any other foods containing pulp material.
- Do not take other laxatives while taking PLENUV.
- Do not take oral medications within 1 hour before or after starting each dose of PLENUV [see *Drug Interactions* (7.2)].

- Ensure completion of Dose 2, including all additional liquids, at least 2 hours before the colonoscopy.

2.2 Two-Day Split-Dosing Regimen

The Two-Day Split-Dosing Regimen commences in the evening of the day before the colonoscopy. Instruct adult patients that on the day before the clinical procedure, they can consume a light breakfast followed by a light lunch, which must be completed at least 3 hours prior to the start of the first PLENUV dose.

Instruct patients to take two separate doses in conjunction with clear liquids as follows: Dose 1 – In the evening before the colonoscopy, between approximately 4 pm and 8 pm:

- Empty the contents of Dose 1 into the mixing container that comes with PLENUV.
- Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENUV solution.
- Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes).
- Drink over the next 30 minutes. Be sure to drink all of the solution.
- Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.
- Consume additional clear liquids during the evening.
- If severe bloating, abdominal distention, or abdominal pain occurs following the first dose, delay the second dose until the symptoms resolve.

Dose 2 – The next morning, on the day of the colonoscopy, approximately 12 hours after the start of Dose 1, between approximately 4 am and 8 am:

- Empty the contents of Dose 2 Pouch A and Dose 2 Pouch B into the mixing container that comes with PLENUV.
 - Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENUV solution.
 - Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes). Drink over the next 30 minutes. Be sure to drink all of the solution.
 - Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.
 - Consume additional water or clear liquids up to 2 hours before the colonoscopy or as prescribed by your doctor. *Then stop drinking liquids until after the colonoscopy.*
- Stop drinking PLENUV temporarily or drink each portion at longer intervals if severe bloating, abdominal discomfort or distention occurs, until these symptoms resolve.

2.3 One-Day Morning Dosing Regimen

The One-Day Morning Dosing Regimen commences in the morning of the day of the colonoscopy.

Instruct adult patients that on the day before the clinical procedure, they can consume a light breakfast followed by a light lunch, and clear broth soup and/or plain yogurt for dinner, which should be completed by approximately 8 pm.

Instruct patients to take two separate doses in conjunction with clear liquids as follows: Dose 1 – On the day of the colonoscopy, between approximately 3 am and 7 am:

- Empty the contents of Dose 1 into the mixing container that comes with PLENUV.
 - Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENUV solution.
 - Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes).
 - Drink over the next 30 minutes.
 - Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.
 - If severe bloating, abdominal distention, or abdominal pain occurs following the first dose, delay the second dose until the symptoms resolve.
- Dose 2 – On the day of the colonoscopy, a minimum of 2 hours after the start of Dose 1:
- Empty the contents of Dose 2 Pouch A and Dose 2 Pouch B into the mixing container that comes with PLENUV.
 - Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENUV solution.
 - Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes). Drink over the next 30 minutes. Be sure to drink all of the solution.
 - Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.
 - Consume additional water or clear liquids up to 2 hours before the colonoscopy or as prescribed by your doctor. *Then stop drinking liquids until after the colonoscopy.*
- Stop drinking PLENUV temporarily or drink each portion at longer intervals if severe bloating, abdominal discomfort or distention occurs, until these symptoms resolve.

CONTRAINDICATIONS

- Gastrointestinal (GI) obstruction (4, 5, 6)
- Bowel perforation (4, 5, 6)
- Gastric retention (4)
- Ileus (4)
- Toxic megacolon (4)
- Hypersensitivity to any ingredient in PLENUV (4, 5, 10)

WARNINGS AND PRECAUTIONS

- Risk of fluid and electrolyte abnormalities:** Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use. (5.1, 5.2, 7.1)
- Cardiac arrhythmias:** Consider pre-dose and post-colonoscopy ECGs in patients at increased risk. (5.2)
- Seizures:** Use caution in patients with a history of seizures and patients at increased risk of seizure, including medications that lower the seizure threshold. (5.3, 7.1)
- Patients with renal impairment or taking concomitant medications that affect renal function:** Use caution, ensure adequate hydration and consider testing. (5.4, 7.1, 8.6)
- Mucosal ulcerations:** Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease. (5.5)
- Suspected GI obstruction or perforation:** Rule out diagnosis before administration. (4, 5, 6)
- Patients at risk for aspiration:** Observe during administration. (5.7)
- Glucose-6-phosphate dehydrogenase deficiency (G6PD):** Use with caution. (5.8)
- Risks in patients with phenyleketonuria:** Contains phenylalanine. (5.9)
- Hypersensitivity reactions, including anaphylaxis:** Inform patients to seek immediate medical care if symptoms occur. (5.10)

ADVERSE REACTIONS

Most common adverse reactions (>2%) are nausea, vomiting, dehydration and abdominal pain/discomfort. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Drugs that increase risks due to fluid and electrolyte change. (7.1)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
Revised: 05/2018

7 DRUG INTERACTIONS

- Drugs That May Increase Risks Due to Fluid and Electrolyte Abnormalities
- Potential for Reduced Drug Absorption
- Stimulant Laxatives

8 USE IN SPECIFIC POPULATIONS

- Pregnancy
- Lactation
- Pediatric Use
- Geriatric Use
- Renal Impairment

10 OVERDOSAGE

12 CLINICAL PHARMACOLOGY

- Mechanism of Action
- Pharmacodynamics
- Pharmacokinetics

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

Storage:

After reconstitution, keep PLENUV solution at room temperature, between 68°F to 77°F (20°C to 25°C) [see USP Controlled Room Temperature]. The solution may also be stored in a refrigerator. Use within 6 hours after it is mixed in water.

3 DOSAGE FORMS AND STRENGTHS

PLENUV (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) is supplied as a white to yellow powder for reconstitution.

First dose: one pouch labeled Dose 1; Second dose: two pouches labeled Dose 2 Pouch A and Dose 2 Pouch B.

- Dose 1 contains 100 grams of polyethylene glycol (PEG) 3350, NF; 9 grams of sodium sulfate, NF; 2 grams of sodium chloride, USP/NF; and 1 gram of potassium chloride, USP/NF.
- Dose 2 Pouch A contains 40 grams of PEG 3350, NF; 3.2 grams of sodium chloride, USP/NF; and 1.2 grams of potassium chloride, USP/NF.
- Dose 2 Pouch B contains 48.11 grams of sodium ascorbate, USP/NF; and 7.54 grams of ascorbic acid, USP/NF.

4 CONTRAINDICATIONS

PLENUV is contraindicated in the following conditions:

- Gastrointestinal (GI) obstruction [see *Warnings and Precautions* (5.6)]
- Bowel perforation [see *Warnings and Precautions* (5.6)]
- Gastric retention
- Ileus
- Toxic megacolon
- Hypersensitivity to any ingredient in PLENUV [see *Warnings and Precautions* (5.10)]

5 WARNINGS AND PRECAUTIONS

5.1 Serious Fluid and Electrolyte Abnormalities

Advise patients to hydrate adequately before, during, and after the use of PLENUV. If a patient develops significant vomiting or signs of dehydration after taking PLENUV, consider performing post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN). Bowel preparations can cause fluid and electrolyte disturbances, which can lead to serious adverse reactions including cardiac arrhythmias, seizures, and renal impairment. Correct fluid and electrolyte abnormalities before treatment with PLENUV. PLENUV should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities [such as diuretics, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)] [see *Drug Interactions* (7.1)]. Consider performing pre-dose and post-colonoscopy laboratory tests (sodium, potassium, calcium, creatinine, and BUN) in patients receiving these concomitant medications.

5.2 Cardiac Arrhythmias

There have been rare reports of serious arrhythmias (including atrial fibrillation) associated with the use of ionic osmotic laxative products for bowel preparation. These occur predominantly in patients with underlying cardiac risk factors and electrolyte disturbances. Use caution when prescribing PLENUV for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, cardiomyopathy or electrolyte imbalance). Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.

5.3 Seizures

There have been rare reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.

Use caution when prescribing PLENUV for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia. [see *Drug Interactions* (7.1)].

5.4 Use in Patients with Renal Impairment

Use PLENUV with caution in patients with renal impairment or patients taking concomitant medications that affect renal function (such as diuretics, ACE inhibitors, angiotensin receptor blockers, or nonsteroidal anti-inflammatory drugs) [see *Drug Interactions* (7.1)]. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration before, during and after the use of PLENUV, and consider performing pre-dose and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see *Use in Specific Populations* (8.6)].

5.5 Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis

Osmotic laxatives may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and PLENUV may increase the risk and is not recommended. Consider the potential for mucosal ulcerations resulting from the bowel preparation when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease.

5.6 Use in Patients with Significant Gastrointestinal Disease

If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering PLENUV [see *Contraindications* (4)]. Use with caution in patients with severe ulcerative colitis.

5.7 Aspiration

Patients with impaired gag reflex or other swallowing abnormalities are at risk for regurgitation or aspiration of PLENUV. Observe these patients during the administration of PLENUV. Use with caution in these patients.

5.8 Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

Since PLENUV contains sodium ascorbate and ascorbic acid, PLENUV should be used with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, especially G6PD deficient patients with an active infection, with a history of hemolysis, or taking concomitant medications known to precipitate hemolytic reactions.

5.9 Risks in Patients with Phenyleketonuria

Phenylalanine can be harmful to patients with phenyleketonuria (PKU). PLENUV contains phenylalanine, a component of aspartame. Each PLENUV treatment contains 491 mg of phenylalanine. Advise patients with PKU to avoid use of PLENUV. Consider the combined daily amount of phenylalanine from all sources, including PLENUV.

5.10 Hypersensitivity Reactions

PLENUV contains PEG and may cause serious hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and pruritus [see *Adverse Reactions* (6.1, 6.2)]. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs and symptoms occur.

6 ADVERSE REACTIONS

The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling:

- Serious Fluid and Electrolyte Abnormalities [see *Warnings and Precautions* (5.1)]
- Cardiac Arrhythmias [see *Warnings and Precautions* (5.2)]
- Seizures [see *Warnings and Precautions* (5.3)]
- Patients with Renal Impairment [see *Warnings and Precautions* (5.4)]
- Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis [see *Warnings and Precautions* (5.5)]
- Patients with Significant Gastrointestinal Disease [see *Warnings and Precautions* (5.6)]
- Aspiration [see *Warnings and Precautions* (5.7)]
- Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency [see *Warnings and Precautions* (5.8)]
- Risks in Patients with Phenyleketonuria [see *Warnings and Precautions* (5.9)]
- Hypersensitivity Reactions [see *Warnings and Precautions* (5.10)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PLENUV as a Two-Day Split-Dosing and One-Day Morning Dosing Regimen was evaluated in two randomized, parallel group, multicenter, investigator-blinded clinical trials (Two-Day Split-Dosing in the NOCT and MORA trials and One-Day Morning Dosing in the MORA trial) in 1351 adult patients undergoing colonoscopy. The mean age of the study population was 56 years (range 18 to 86 years), 92% of patients were Caucasian and 51% were female. In the NOCT trial, 61% of patients had mild renal impairment. In the MORA trial, 67% had mild renal impairment and 5% had moderate renal impairment. Patients with severe renal impairment were not enrolled in the clinical trials [see *Clinical Studies* (14)].

The most common adverse reactions (>2%) in the PLENUV treatment groups in both trials were: nausea, vomiting, dehydration and abdominal pain/discomfort.

Table 1 and Table 2 display adverse reactions reported in at least 1% of patients in one or more treatment groups in the NOCT and MORA trials, respectively. Since diarrhea was considered as a part of the efficacy assessment, it was not defined as an adverse reaction in these trials.

Table 1: Common Adverse Reactions* in Patients Undergoing Colonoscopy in the NOCT Trial by Treatment Group

Preferred Term	PLENUV Two-Day Split Dosing Regimen (N = 275)		Trisulfate ¹ Two-Day Split Dosing Regimen (N = 271)	
	%	n	%	n
Nausea	7	2	2	2
Vomiting	6	3	3	3
Dehydration ²	4	2	2	2
Abdominal Pain/Discomfort ³	2	2	2	2
Decline in Glomerular Filtration Rate (GFR) ⁴	2	2	2	2
Electrolyte Abnormalities ⁵	2	1	1	1
Fatigue	2	1	1	1
Headache	2	1	1	1
Abdominal Distension	1	1	1	1
Gastritis	1	1	1	1
Hiatus Hernia	1	0	0	0
Nasopharyngitis	1	1	1	1

* Reported in at least 1% of patients in either treatment group

N = Total number of patients in the treatment group; n = the number of patients with the adverse reaction

¹ Trisulfate: Two 6 ounce bottles of oral solution each containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, magnesium sulfate 1.6 grams

² Includes signs and symptoms of dehydration, including dizziness, dry mouth, orthostatic hypotension, pre-syncope, syncope, and thirst

³ Includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and abdominal tenderness

⁴ Decreased or abnormal GFR

⁵ Includes increased anion gap, decreased blood bicarbonate, hypomagnesemia, hyperosmolality, hypokalemia, hyperkalemia, hypercalcemia, hypernatremia, hyperosmolar state, hyperuricemia, hypocalcemia, and hypophosphatemia

Table 2: Common Adverse Reactions* in Patients Undergoing Colonoscopy in the MORA Trial by Treatment Group

Preferred Term	PLENUV One-Day Morning Dosing Regimen (N = 271)		PLENUV Two-Day Split Dosing Regimen (N = 265)		2 Liter PEG + Electrolytes Two-Day Split-Dosing Regimen ¹ (N = 269)	
	%	n	%	n	%	n
Vomiting	7	4	4	3	3	3
Nausea	6	6	3	1	1	1
Dehydration ²	4	3	2	2	2	2
Abdominal Pain/Discomfort ³	3	2	3	3	3	3
Hypertension ⁴	2	1	0	0	0	0
Headache	1	2	2	2	2	2
Electrolyte Abnormalities ⁵	1	1	1	0	0	0

* Reported in at least 1% of patients in either treatment group

N = Total number of patients in the treatment group; n = the number of patients with the adverse reaction

¹ 2 Liter PEG Plus Electrolytes: Two doses each containing PEG 3350 100 grams, sodium sulfate 7.5 grams, sodium chloride 2.691 grams, potassium chloride 1.015 grams, sodium ascorbate 5.9 grams, and ascorbic acid 4.7 grams

² Includes signs and symptoms of dehydration, including dizziness, dry mouth, orthostatic hypotension, pre-syncope, syncope, and thirst

³ Includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and abdominal tenderness

⁴ Includes increased anion gap, decreased blood bicarbonate, hypomagnesemia, increased blood osmolality, hypokalemia, hyperkalemia, hypercalcemia, hypernatremia, hyperosmolar state, hyperuricemia, hypocalcemia, and hypophosphatemia

Electrolyte Changes

Increases in serum sodium, chloride, calcium, magnesium, phosphate, and urate were noted in more patients treated with PLENUV compared with control in one or both trials. The majority of these changes were transient and not clinically significant. Associated decreases in bicarbonate and increases in serum osmolality were also noted.

Renal Function

Decreases in creatinine clearance and increases in blood urea nitrogen (BUN) were also noted in more patients treated with PLENUV compared to control in both trials. Changes of a magnitude indicative of possible acute renal injury, or worsening of baseline chronic renal impairment, were noted infrequently and occurred at a similar incidence in both PLENUV and comparator arms.

Adverse reactions in patients with mild renal impairment were similar to those in patients with normal renal function.

Less Common Adverse Reactions
Less common adverse reactions (less than 1%) in the NOCT and MORA trials include: anorectal discomfort, hypersensitivity reaction (including rash), migraine, somnolence, asthenia, chills, pains, aches, palpitation, sinus tachycardia, hot flush, and transient increase in liver enzymes.

An additional 235 patients were exposed to the One-Day Morning Dosing Regimen of PLENUV in a third clinical trial, utilizing a comparator not approved in the United States. The adverse reaction profile for patients receiving PLENUV in that trial was similar to what is described above.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of another oral formulation of polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride or other polyethylene glycol (PEG)-based bowel preparations. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity: urticaria/rash, pruritus, dermatitis, rhinorrhea dyspnea, chest and throat tightness, fever, angioedema, anaphylaxis and anaphylactic shock [see *Contraindications* (4)]
Cardiovascular: arrhythmia, atrial fibrillation, peripheral edema, asystole, and acute pulmonary edema after aspiration


MEDICATION GUIDE PLENVU® (plen-vu) (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution)
<p>Read this Medication Guide and Instructions for Use before your colonoscopy and again before you start taking PLENVU.</p> <p>What is the most important information I should know about PLENVU? PLENVU and other bowel preparations can cause serious side effects, including:</p> <ul style="list-style-type: none"> • Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood. These changes can cause: <ul style="list-style-type: none"> ○ abnormal heartbeats that can cause death. ○ seizures. This can happen even if you have never had a seizure. ○ kidney problems. <p>Your chance of having fluid loss and changes in body salts with PLENVU is higher if you:</p> <ul style="list-style-type: none"> • have heart problems. • have kidney problems. • take water pills (diuretics), high blood pressure medicine or non-steroidal anti-inflammatory drugs (NSAIDs). <p>Tell your healthcare provider right away if you have any of these symptoms of serious loss of body fluid (dehydration) while taking PLENVU:</p> <ul style="list-style-type: none"> • vomiting • dizziness • urinating less often than normal • headache <p>See “What are the possible side effects of PLENVU?” for more information about side effects.</p>
<p>What is PLENVU? PLENVU is a prescription medicine used by adults to clean the colon before a colonoscopy. PLENVU cleans your colon by causing you to have diarrhea (loose stools). Cleaning your colon helps your healthcare provider see the inside of your colon more clearly during your colonoscopy. It is not known if PLENVU is safe and effective in children.</p> <p>Do not take PLENVU if your healthcare provider has told you that you have:</p> <ul style="list-style-type: none"> • a blockage in your intestine (bowel obstruction). • an opening in the wall of your stomach or intestine (bowel perforation). • problems with food and fluid emptying from your stomach (gastric retention). • a problem with food moving too slowly through your intestines (ileus). • a very dilated intestine (toxic megacolon). • an allergy to any of the ingredients in PLENVU. See the end of this leaflet for a complete list of ingredients in PLENVU.
<p>Before taking PLENVU, tell your healthcare provider about all of your medical conditions, including if you:</p> <ul style="list-style-type: none"> • have problems with serious loss of body fluid (dehydration) and changes in blood salts (electrolytes). • have heart problems. • have seizures or take medicines for seizures. • have kidney problems or take medicines for kidney problems. • have stomach or bowel problems, including ulcerative colitis. • have problems with swallowing, gastric reflux or if you inhale food or fluid into your lungs when eating or drinking (aspirate). • have a condition called glucose-6-phosphate dehydrogenase (G6PD) deficiency that destroys red blood cells. • are withdrawing from drinking alcohol. • have phenylketonuria (PKU). PLENVU contains phenylalanine. • are allergic to any of the ingredients in PLENVU. • are pregnant or plan to become pregnant. It is not known if PLENVU will harm your unborn baby. Talk to your healthcare provider if you are pregnant. • are breastfeeding or plan to breastfeed. It is not known if PLENVU passes into your breast milk. You and your healthcare provider should decide if you will take PLENVU while breastfeeding. <p>Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. PLENVU may affect how other medicines work. Do not take medicines by mouth 1 hour before or after the start of PLENVU. Especially tell your healthcare provider if you take:</p> <ul style="list-style-type: none"> • medicines to treat a blood salt (electrolyte) imbalance. • medicines for blood pressure or heart problems. • medicines for seizures (antiepileptics). • medicines for kidney problems. • water pills (diuretics). • non-steroidal anti-inflammatory drugs (NSAIDs). • laxatives. Do not take other laxatives while taking PLENVU. • medicines for depression or other mental health problems. <p>Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure if you are taking any of the medicines listed above. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p>How should I take PLENVU? See the “Instructions for Use” for dosing instructions. You must read, understand, and follow these instructions to take PLENVU the right way.</p> <ul style="list-style-type: none"> • Take PLENVU exactly as your healthcare provider tells you to take it. Your healthcare provider will tell you to take the Two-Day Split-Dosing option or the One-Day Morning Dosing option. • Drink only clear liquids before, during, and after you take PLENVU, until 2 hours before your colonoscopy to help prevent fluid loss (dehydration). • Do not eat solid food while taking PLENVU until after your colonoscopy. • It is important for you to drink the additional amount of clear liquids listed in the <i>Instructions for Use</i>. • You may have stomach-area (abdomen) bloating after your first dose of PLENVU. <ul style="list-style-type: none"> ○ If you have severe stomach-area (abdomen) discomfort or bloating, stop drinking PLENVU for a short time or wait a longer time between each dose of PLENVU until your stomach-area symptoms improve. If your stomach-area discomfort or bloating continues, tell your healthcare provider. • Your first bowel movement may happen about 1 to 2 hours after you start taking PLENVU. • If you take too much PLENVU, call your healthcare provider.
<p>What are the possible side effects of PLENVU? PLENVU can cause serious side effects including:</p> <ul style="list-style-type: none"> • Changes in certain blood tests. Your healthcare provider may do blood tests after you take PLENVU to check your blood for changes. Tell your healthcare provider if you have any symptoms of too much fluid loss, including: <ul style="list-style-type: none"> ○ vomiting ○ dizziness ○ feel faint, weak or lightheaded especially when you stand up (orthostatic hypotension) ○ heart problems ○ kidney problems ○ dry mouth • Ulcers of the bowel or bowel problems (ischemic colitis): Tell your healthcare provider right away if you have severe stomach-area (abdomen) pain or rectal bleeding. • Serious allergic reactions. Symptoms of a serious allergic reaction may include: <ul style="list-style-type: none"> ○ skin rash ○ itching ○ nausea ○ stomach pain or discomfort ○ raised red patches on your skin (hives) ○ swelling of the face, lips, tongue and throat ○ vomiting ○ dehydration ○ kidney problems <p>The most common side effects of PLENVU include:</p> <ul style="list-style-type: none"> ○ nausea ○ stomach pain or discomfort ○ vomiting ○ dehydration <p>These are not all the possible side effects of PLENVU. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>How should I store PLENVU?</p> <ul style="list-style-type: none"> • Store PLENVU (before opening and after mixed) at room temperature, between 68°F to 77°F (20°C to 25°C). PLENVU may also be stored in a refrigerator. • Use PLENVU within 6 hours after mixing with water. <p>Keep PLENVU and all medicines out of the reach of children.</p>
<p>General information about the safe and effective use of PLENVU. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use PLENVU for a condition for which it was not prescribed. Do not give PLENVU to other people, even if they are going to have the same procedure you are. It may harm them. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.</p>
<p>What are the ingredients in PLENVU? Active ingredient: Dose 1: PEG 3350, sodium sulfate, sodium chloride, potassium chloride Dose 2 Pouch A: PEG 3350, sodium chloride, potassium chloride Dose 2 Pouch B: sodium ascorbate, ascorbic acid Inactive ingredients: Dose 1: sucralose, encapsulated citric acid, mango flavoring Dose 2 Pouch A: aspartame, fruit punch flavoring</p>
<p>Manufactured for: Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC Bridgewater, NJ 08807 USA</p> <p>Manufactured by: Norgine Limited 7 Tir-y-berth Industrial Estate New Road, Tir-y-berth Hengoed, CF82 8SJ United Kingdom (GBR)</p> <p>U.S. Patent Numbers: 8,999,313; 9,326,969; 9,592,252; and 9,707,297 Please see www.salix.com for patent information. PLENVU is a registered trademark of the Norgine group of companies used under license. © Valeant Pharmaceuticals North America LLC For more information, go to www.PLENVU.com or call 1-800-321-4576.</p>

Instructions for Use PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution)

There are two different options for taking PLENVU. Your healthcare provider will tell you to take the Two-Day Split-Dosing option or the One-Day Morning Dosing option.




The following are provided with the pack:

- An outer carton:
- An inner carton:
- A mixing container with removable lid:
- Prescribing Information and Patient Information



The inner carton contains:

- Dose 1
- Dose 2 Pouch A and Dose 2 Pouch B (to be taken together)



Additional supplies:

- Water (to mix with PLENVU).
- Scissors (optional to cut the pouches on the dotted line).
- Spoon (optional to mix the water and PLENVU together. You can also mix the water and PLENVU by putting the lid on securely and shaking it. See step 1c below).

Important Information on PLENVU:

- You must drink all of Dose 1 (one pouch) and Dose 2 (two pouches) of PLENVU for either dosing option. Make sure you finish Dose 2 at least 2 hours before your colonoscopy. **Do not** add any other ingredients to PLENVU.
- PLENVU **must** be mixed with water.
- Drink clear liquids before, during, and after you take PLENVU, up until 2 hours before your colonoscopy, to help prevent fluid loss (dehydration). It is important for you to drink the additional amount of clear liquids listed here in the Instructions for Use.

Examples of clear liquids are:


- water
- clear broth soups
- herbal tea, black tea or coffee
- watered down (diluted) (from concentrate) clear fruit juices (without pulp) including apple juice or white grape juice
- clear soda
- gelatin (without added fruit or topping)
- popsicles (without pieces of fruit or fruit pulp)
- strained limeade or lemonade
- **Do not** eat or drink alcohol, milk, anything colored red or purple or any foods that have pulp.
- **Do not** take other laxatives while taking PLENVU.
- **Do not** take any medicines by mouth (oral) within 1 hour before or after starting each dose of PLENVU.
- **Do not** eat solid food while taking PLENVU until after your colonoscopy.
- For the Two-Day Split-Dosing schedule:
 - On the day before the colonoscopy you can eat a light breakfast followed by a light lunch.
 - You must finish eating lunch at least 3 hours before you start taking PLENVU.
 - After you start taking PLENVU you can only drink clear liquids.
- For the One-Day Morning Dosing schedule:
 - On the day before the colonoscopy you can eat a light breakfast followed by a light lunch. For dinner you may have clear broth soup and/or plain yogurt.
 - You should finish dinner by about 8 pm.
 - After you start taking PLENVU you can only drink clear liquids.
- **Do not** eat the morning of your colonoscopy.

Two-Day Split-Dosing Schedule

Take Dose 1 in the evening sometime between 4 pm and 8 pm.
Take Dose 2 the next morning, on the day of the colonoscopy. This should be about 12 hours (between about 4 am and 8 am) after you started Dose 1. Make sure you finish Dose 2 at least 2 hours before your colonoscopy.

Follow steps 1 through 3 on how to mix with a spoon or shake with lid on securely and take PLENVU:


- Step 1a:** Empty Dose 1 into the mixing container that comes with your PLENVU.



- Step 1b:** Add water to the fill line. You will need to add least 16 ounces.




- Step 1c:** Mix the water and PLENVU together with a spoon or put lid on mixing container securely and shake the water and PLENVU, until it is completely dissolved. This can take 2 to 3 minutes.



- Step 2:** Drink the entire contents of the mixing container over the next 30 minutes. If you feel like you have severe stomach pain or discomfort you can stop taking PLENVU for a short time and then continue taking it or you can take smaller sips of PLENVU so that you space out your dose longer than 30 minutes. If you still have severe stomach pain, call your healthcare provider.




- Step 3:** Rinse the mixing container with water. Refill to the fill line with clear liquids. This will be at least 16 ounces. Drink the entire contents of the mixing container over the next 30 minutes. **Continue to drink additional clear liquids during the evening.** For a list of clear liquids, see examples at the top of the Instructions for Use.



After taking PLENVU if you have any bloating or feeling like your stomach is upset, wait to take Dose 2 until your stomach feels better.

- For Dose 2:** Rinse the mixing container with water. Repeat Steps 1, 2 and 3 but this time for Dose 2 you will empty two dose pouches (Dose 2 Pouch A and Dose 2 Pouch B) into the mixing container at the same time. **It is important that you drink additional clear liquids, but you must stop drinking all liquids 2 hours before your colonoscopy.**




One-Day Morning Dosing Schedule

Take Dose 1 the morning of your colonoscopy sometime between 3 am and 7 am.
Take Dose 2 about two hours after you start Dose 1. Make sure you finish Dose 2 at least 2 hours before your colonoscopy.

Follow the steps 1 through 3 on how to mix with a spoon or shake with lid on securely and take PLENVU:


- Step 1a:** Empty Dose 1 into the mixing container that comes with your PLENVU.



- Step 1b:** Add water to the fill line. You will need to add least 16 ounces.




- Step 1c:** Mix the water and PLENVU together with a spoon or put lid on mixing container securely and shake the water and PLENVU, until it is completely dissolved. This can take 2 to 3 minutes.



- Step 2:** Drink the entire contents of the mixing container over the next 30 minutes. If you feel like you have severe stomach pain or discomfort you can stop taking PLENVU for a short time and then continue taking it or you can take smaller sips of PLENVU so that you space out your dose longer than 30 minutes. If you still have severe stomach pain, call your healthcare provider.




- Step 3:** Rinse the mixing container with water. Refill to fill line with clear liquids. This will be at least 16 ounces. Drink the entire contents of the mixing container over the next 30 minutes. For a list of clear liquids, see examples at the top of the Instructions for Use.



After taking PLENVU if you have any bloating or feeling like your stomach is upset, wait to take Dose 2 until your stomach feels better.

- For Dose 2:** Rinse the mixing container with water. Repeat Steps 1, 2 and 3 but this time for Dose 2 you will empty two dose pouches (Dose 2 Pouch A and Dose 2 Pouch B) into the mixing container at the same time. **It is important that you drink additional clear liquids, but you must stop drinking all liquids 2 hours before your colonoscopy.**



Manufactured for:

Salix Pharmaceuticals, a division of
Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA

Manufactured by:

Norgine Limited
7 Tir-y-berth Industrial Estate
New Road, Tir-y-berth
Hengoed, CF82 8SJ
United Kingdom (GBR)

U.S. Patent Numbers: 8,999,313; 9,326,969; 9,592,252; and 9,707,297
Please see www.salix.com for patent information.

PLENVU is a registered trademark of the Norgine group of companies used under license.

© Valeant Pharmaceuticals North America LLC

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Issued: May 2018

9643000

70013541